NCT05445895View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Renexin CR in Patients With Acute Non-cardioembolic Ischemic Stroke

PHASE4RecruitingINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

December 16, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

October 31, 2025

Conditions
Ischemic Stroke
Interventions
DRUG

Renexin CR 200/160mg

Renexin CR 200/160mg will be added to Aspirin 100mg

DRUG

Plavix 75mg

Plavix 75mg will be added to Aspirin 100mg

Trial Locations (1)

Unknown

RECRUITING

Asan Medical Center, Seoul

All Listed Sponsors
lead

SK Chemicals Co., Ltd.

INDUSTRY